Pidilizumab
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Pidilizumab
Pidilizumab (formerly CT-011) is a monoclonal antibody being developed by Medivation for the treatment of cancer and infectious diseases. Pidilizumab was originally thought to bind to the PD-1 immune checkpoint molecule, however, recent evidence suggests that Delta-like 1 (DLL1) is its primary binding target while binding to PD-1 is secondary and restricted to non-glycosylated and hypoglycosylated forms of this molecule. Pidilizumab causes in the attenuation of apoptotic processes in lymphocytes, primarily effector/memory T cells.
has abstract
Pidilizumab (formerly CT-011) ...... arily effector/memory T cells.
@en
CAS number
1036730-42-3
FDA UNII code
B932PAQ1BQ
KEGG
Wikipage page ID
36,964,640
page length (characters) of wiki page
Wikipage revision ID
984,406,447
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
KEGG
D10390
@en
mab type
mab
@en
source
zu/o
@en
target
type
mab
@en
UNII
B932PAQ1BQ
@en
wikiPageUsesTemplate
hypernym
comment
Pidilizumab (formerly CT-011) ...... arily effector/memory T cells.
@en
label
Pidilizumab
@en